An Abbreviated Course of Therapeutic Plasma Exchange Does Not Affect Platelet Count Recovery or Durability in Patients With Immune Thrombotic Thrombocytopenic Purpura Receiving Caplacizumab
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2026
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867003010106785792 |
|---|---|
| author | Jay S. Raval Erika Hochhaus Grace M. Lee |
| author_facet | Jay S. Raval Erika Hochhaus Grace M. Lee Jay S. Raval Erika Hochhaus Grace M. Lee |
| collection | Wiley Open Access |
| contents | An Abbreviated Course of Therapeutic Plasma Exchange Does Not Affect Platelet Count Recovery or Durability in Patients With Immune Thrombotic Thrombocytopenic Purpura Receiving Caplacizumab Jay S. Raval Erika Hochhaus Grace M. Lee Journal of Clinical Apheresis ABSTRACT Patients with immune thrombotic thrombocytopenic purpura (iTTP) receive daily therapeutic plasma exchange (TPE) and immunosuppression as first‐line therapies. It is recommended that TPE be performed until clinical response is achieved, typically defined as platelet counts ≥ 150 × 10 9 /L for ≥ 2 consecutive days. The anti‐von Willebrand factor agent caplacizumab is approved for patients with iTTP in combination with TPE and immunosuppression and has been shown to more rapidly normalize platelet counts and decrease exacerbations, refractoriness, and mortality. However, no studies have re‐examined endpoints for TPE cessation with concomitant caplacizumab use. We compared patients with iTTP receiving daily TPE, immunosuppression, and caplacizumab who had the typically recommended TPE treatment course versus an abbreviated course with TPE discontinued before achieving platelet counts of 150 × 10 9 /L and observed no detriment with early TPE cessation. Additional high‐quality studies re‐evaluating daily TPE cessation endpoints are needed for patients with iTTP receiving caplacizumab. 10.1002/jca.70127 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1002/jca.70127 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_jca_70127 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2026 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | An Abbreviated Course of Therapeutic Plasma Exchange Does Not Affect Platelet Count Recovery or Durability in Patients With Immune Thrombotic Thrombocytopenic Purpura Receiving Caplacizumab Jay S. Raval Erika Hochhaus Grace M. Lee Journal of Clinical Apheresis An Abbreviated Course of Therapeutic Plasma Exchange Does Not Affect Platelet Count Recovery or Durability in Patients With Immune Thrombotic Thrombocytopenic Purpura Receiving Caplacizumab Jay S. Raval Erika Hochhaus Grace M. Lee Journal of Clinical Apheresis ABSTRACT Patients with immune thrombotic thrombocytopenic purpura (iTTP) receive daily therapeutic plasma exchange (TPE) and immunosuppression as first‐line therapies. It is recommended that TPE be performed until clinical response is achieved, typically defined as platelet counts ≥ 150 × 10 9 /L for ≥ 2 consecutive days. The anti‐von Willebrand factor agent caplacizumab is approved for patients with iTTP in combination with TPE and immunosuppression and has been shown to more rapidly normalize platelet counts and decrease exacerbations, refractoriness, and mortality. However, no studies have re‐examined endpoints for TPE cessation with concomitant caplacizumab use. We compared patients with iTTP receiving daily TPE, immunosuppression, and caplacizumab who had the typically recommended TPE treatment course versus an abbreviated course with TPE discontinued before achieving platelet counts of 150 × 10 9 /L and observed no detriment with early TPE cessation. Additional high‐quality studies re‐evaluating daily TPE cessation endpoints are needed for patients with iTTP receiving caplacizumab. 10.1002/jca.70127 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | An Abbreviated Course of Therapeutic Plasma Exchange Does Not Affect Platelet Count Recovery or Durability in Patients With Immune Thrombotic Thrombocytopenic Purpura Receiving Caplacizumab |
| topic | Journal of Clinical Apheresis |
| url | https://onlinelibrary.wiley.com/doi/10.1002/jca.70127 |